Renal & Urinary

Hyponatremia: evaluation by volume status and management

Clinical Overview and When to Suspect Hyponatremia

— Exception: true sodium losses (diuretics, GI/skin losses) contribute, but ADH-mediated water retention seals the diagnosis.

— Elderly patient on thiazide with new confusion, gait instability, or fall

— Postoperative patient receiving hypotonic IVF (D5W, ½NS) with headache, nausea, seizure

— Marathon runner, ecstasy user, or psychogenic polydipsia with altered mental status

— Small-cell lung cancer, CNS disease, or pneumonia (SIADH triggers)

— CHF, cirrhosis, nephrotic syndrome with worsening edema and Na <130

— Adrenal insufficiency: hypotension + hyperkalemia + hyponatremia

— Acute (<48 h): brain has not adapted; risk is cerebral edema → correct faster

— Chronic (>48 h or unknown duration): brain has osmolytes extruded; risk is osmotic demyelination syndrome (ODS) if corrected too fast

— Severe symptoms: seizures, coma, obtundation, vomiting, respiratory arrest → hypertonic saline regardless of chronicity

— Moderate: headache, confusion, nausea, gait disturbance

— Mild/asymptomatic: outpatient workup acceptable

Definition: serum sodium <135 mEq/L; severe <125 mEq/L. Most common electrolyte disorder in hospitalized adults (15–30%).

Pathophysiology core concept: hyponatremia is almost always a problem of water excess (impaired free water excretion), not sodium deficit. ADH activity — appropriate or inappropriate — is the central driver.

When to suspect on Step 3 vignettes:

Acute vs chronic threshold = 48 hours. This determines correction rate and risk of osmotic demyelination.

Symptom severity drives urgency, not the number alone:

Step 3 management: the first three labs in any hyponatremia workup are serum osmolality, urine osmolality, and urine sodium — order them simultaneously with volume status assessment. This single triad resolves the vast majority of cases and is the highest-yield ordering pattern on CCS hyponatremia cases.

Board pearl: a "normal" or elevated serum osmolality in a hyponatremic patient means you are dealing with pseudo- or translocational hyponatremia, not true hypotonic hyponatremia — stop and reassess before treating.

Presentation Patterns and Key History

— Mild (Na 130–134): often asymptomatic, subtle cognitive slowing, fatigue

— Moderate (125–129): headache, nausea, lethargy, unsteady gait, falls

— Severe (<125 or rapid drop): vomiting, seizures, obtundation, coma, non-cardiogenic pulmonary edema, brainstem herniation

— Medications: thiazides (HCTZ, chlorthalidone — classic elderly woman), SSRIs, SNRIs, carbamazepine/oxcarbazepine, desmopressin, NSAIDs, MDMA, cyclophosphamide, vincristine, PPIs

— Fluid intake: beer potomania ("tea and toast" diet — low solute intake limits free water excretion), psychogenic polydipsia, marathon overhydration, post-TURP irrigation

— Volume losses: vomiting, diarrhea, NG suction, diuretic use, burns, pancreatitis (third-spacing)

— Comorbidities: CHF, cirrhosis, nephrotic syndrome, CKD, hypothyroidism, adrenal insufficiency, malignancy (especially SCLC, head/neck), recent CNS event (stroke, SAH, trauma, meningitis), recent pulmonary disease

— Surgical/anesthesia history: postop SIADH from pain, nausea, opioids, and hypotonic fluids is a Step 3 favorite

Neurologic symptoms dominate and reflect cerebral edema from water shifting intracellularly. Severity correlates with both rate of fall and absolute level.

Key history questions — build these into every CCS encounter:

Timing matters: ask when Na was last normal. A patient with Na 118 found on routine labs who is walking and talking almost certainly has chronic hyponatremia — correcting fast will harm them.

Key distinction: acute symptomatic hyponatremia (e.g., postop, ecstasy use, marathon, post-TURP) presents within hours with seizures/coma and tolerates rapid correction; chronic hyponatremia in an elderly thiazide user with confusion mandates slow, deliberate correction even if Na is 115.

Board pearl: the symptomatic marathon runner who collapsed at the finish line and has Na 122 — give hypertonic saline immediately; do not wait for osmolality results. Acute exercise-associated hyponatremia is the prototype where speed saves the brain.

Physical Exam Findings and Volume Status Assessment

— Dry mucous membranes, decreased skin turgor, sunken eyes

— Orthostatic hypotension, tachycardia, flat JVP

— Oliguria, concentrated urine

— Causes: diuretics (especially thiazides), vomiting, diarrhea, third-spacing (pancreatitis, burns, bowel obstruction), cerebral/renal salt wasting, adrenal insufficiency

— Normal turgor, moist mucosa, no edema, no JVD

— Causes: SIADH (most common), hypothyroidism, glucocorticoid deficiency, primary polydipsia, beer potomania, reset osmostat

— Peripheral edema, ascites, elevated JVP, S3, crackles, hepatomegaly, weight gain

— Causes: CHF, cirrhosis, nephrotic syndrome, advanced CKD

Volume status is the diagnostic fork in the road — assess before ordering anything else and document explicitly on CCS.

Hypovolemic hyponatremia — losing both Na and water, but water replaced (often hypotonically):

Euvolemic hyponatremia — total body water mildly increased, no edema, normal BP:

Hypervolemic hyponatremia — total body water markedly increased:

Neurologic exam: mental status, gait (tandem gait sensitive for subtle encephalopathy), asterixis (cirrhosis), focal deficits (pre-existing CNS disease unmasked).

Key distinction: SIADH vs cerebral salt wasting (CSW) — both have elevated urine Na and urine osm. SIADH = euvolemic; CSW = hypovolemic (often after SAH, TBI). Treatment diverges: SIADH gets fluid restriction; CSW gets salt and volume. Misclassifying CSW as SIADH and restricting fluids worsens cerebral ischemia.

Step 3 management: in a hospitalized patient, daily weights, strict I/Os, and orthostatics are cheap, repeat-orderable, and the highest-yield bedside data for tracking volume trajectory — order them on every CCS hyponatremia case.

Board pearl: the edematous hyponatremic patient (CHF, cirrhosis) has the worst prognosis — Na <130 in heart failure independently predicts mortality, and the treatment is fluid + sodium restriction, not saline. Giving normal saline here worsens edema and rarely raises Na.

Diagnostic Workup — Initial Labs

— Serum osmolality: confirms true hypotonic hyponatremia (<275 mOsm/kg)

— Urine osmolality: assesses ADH activity

— Urine sodium: assesses renal Na handling and volume status

— Low (<275): true hypotonic hyponatremia → proceed with volume-status workup

— Normal (275–295): pseudohyponatremia — severe hyperlipidemia or hyperproteinemia (multiple myeloma, IVIG); spurious lab artifact with indirect ISE

— High (>295): translocational — hyperglycemia (correct Na by 1.6–2.4 mEq/L per 100 mg/dL glucose above 100), mannitol, glycine (post-TURP), maltose (IVIG)

— <100 mOsm/kg: appropriately dilute urine → ADH suppressed → primary polydipsia, beer potomania, low solute intake, reset osmostat (low end)

— >100: ADH is active (appropriately or inappropriately) → use volume status + urine Na next

— <20 mEq/L: avid Na retention → hypovolemia (extrarenal losses: GI, skin, third-spacing) OR hypervolemic states (CHF, cirrhosis, nephrotic)

— >40 mEq/L: renal Na wasting → SIADH, diuretics, adrenal insufficiency, salt-wasting nephropathy, CSW

The diagnostic triad — order simultaneously:

Step 1 — Serum osmolality:

Step 2 — Urine osmolality (in true hypotonic hyponatremia):

Step 3 — Urine sodium (when UOsm >100):

Additional initial labs: BMP (K, BUN, Cr, glucose), TSH, morning cortisol or ACTH stim, uric acid (low in SIADH, high in CSW/hypovolemia), urinalysis.

Step 3 management: always check TSH and cortisol before labeling as SIADH — undiagnosed hypothyroidism or adrenal insufficiency masquerading as SIADH is a classic miss. Empiric stress-dose hydrocortisone is reasonable if shock or suggestive features.

Board pearl: fractional excretion of urea (FEUrea) <35% suggests hypovolemia even in diuretic users (where FENa is unreliable). Low uric acid + high FEUrate (>12%) supports SIADH.

Diagnostic Workup — Advanced and Confirmatory Studies

— Hypotonic hyponatremia (SOsm <275)

— Inappropriately concentrated urine (UOsm >100)

— Urine Na >40 (on normal salt/water intake)

— Clinical euvolemia

— Normal thyroid and adrenal function

— Absence of diuretic use

— CNS: head CT/MRI if neuro symptoms — stroke, SAH, tumor, abscess, hydrocephalus

— Pulmonary: CXR — pneumonia, small cell lung cancer (low-dose chest CT if smoker), TB

— Malignancy: SCLC, head/neck squamous, GU, lymphoma — age-appropriate screening

— Drugs: thorough med reconciliation (SSRIs, carbamazepine, oxcarbazepine, cyclophosphamide, vincristine, MDMA, opioids, antipsychotics, NSAIDs)

— HIV testing if risk factors (HIV-associated nephropathy and opportunistic CNS disease both cause SIADH)

— Unexplained SIADH in a smoker → chest CT to rule out SCLC

— Focal neuro signs or seizure → head imaging

— Suspected ODS post-correction → MRI brain (T2 hyperintensity in central pons, classic 1–3 weeks after rapid correction)

Confirming SIADH (Bartter-Schwartz criteria — all required):

Etiology workup once SIADH confirmed — find the cause:

Water deprivation/saline infusion tests: rarely needed; reset osmostat suggested by stable Na 125–135 with normal regulation of further water loads.

Copeptin (surrogate for ADH): not standard in US practice; emerging but not Step 3 expected.

Imaging triggers:

Key distinction: SIADH vs reset osmostat — reset osmostat patients defend a lower Na set point (~125–130), still dilute urine with water loads, do not progress, and require no treatment. Common in pregnancy, quadriplegia, chronic malnutrition, psychiatric illness.

Board pearl: persistent unexplained SIADH in an older smoker mandates chest CT even with normal CXR — SCLC ectopic ADH can precede radiographically visible disease by months. Document the negative workup in the chart.

Step 3 management: on CCS, after diagnosing SIADH, advance the clock and reassess Na, weight, urine output, and mental status every 4–6 hours during active correction.

Risk Stratification and First-Line Management Logic

— 1) Symptom severity (severe/moderate/mild)

— 2) Acuity (<48 h vs ≥48 h/unknown)

— 3) Volume status (hypo/eu/hypervolemic)

— Maximum 6–8 mEq/L in 24 hours (some guidelines allow up to 10–12 in low-risk patients; safer ceiling is 8)

— Maximum 18 mEq/L in 48 hours

— In high ODS-risk patients (Na <105, hypokalemia, malnutrition, alcoholism, advanced liver disease), cap at 4–6 mEq/L/24 h

— 3% hypertonic saline 100 mL IV bolus over 10 min, may repeat up to 3 times until symptoms resolve or Na rises 4–6 mEq/L

— Goal: rapid 4–6 mEq/L rise, then slow — this reverses herniation risk without overshooting

— ICU admission, q2h Na checks

— Hypovolemic: isotonic (0.9%) saline — restores volume, suppresses ADH, allows water diuresis (watch for overcorrection once ADH turns off!)

— Euvolemic (SIADH): fluid restriction (<800–1000 mL/day) first-line; add salt tabs, loop diuretic, urea, or vaptan if inadequate

— Hypervolemic: fluid + sodium restriction + loop diuretic + treat underlying disease (afterload reduction in CHF, large-volume paracentesis in cirrhosis)

Three branch points drive every decision:

Correction rate limits — memorize cold:

Severe symptomatic (seizure, coma, severe vomiting):

Moderate symptomatic: 3% saline infusion (15–30 mL/h) or 100 mL boluses; less urgent but still hypertonic.

Asymptomatic/mild: treat the underlying cause based on volume status — no hypertonic saline.

Volume-status-directed therapy:

CCS pearl: when starting 3% saline, order q2h sodium checks and write an explicit hold parameter ("hold infusion if Na rises >6 mEq/L in 24 h"). Boards reward demonstrating awareness of overcorrection risk.

Board pearl: if you overshoot — Na rises too fast — re-lower it with D5W ± DDAVP 2–4 mcg IV. This "DDAVP clamp" strategy is increasingly favored prophylactically in high-risk patients to prevent overcorrection.

Pharmacotherapy — First-Line and Adjunct Agents

— Na concentration 513 mEq/L

— Severe symptomatic: 100 mL bolus over 10 min × up to 3 (target 4–6 mEq/L rise)

— Continuous infusion alternative: estimate using Adrogue-Madias formula: ΔNa per L infusate = (infusate Na − serum Na) / (TBW + 1); but bolus dosing is now preferred and safer

— Central line not required for short-term peripheral 3% saline

— Predictors of failure: UOsm >500, urine Na+K > serum Na, 24-h urine output <1.5 L

— Tolvaptan (oral V2 antagonist), conivaptan (IV V1a/V2)

— Indicated for euvolemic or hypervolemic hyponatremia

— Boxed warning: hepatotoxicity (tolvaptan); limit to <30 days; do not use in liver disease

— Initiate inpatient with frequent Na monitoring due to overcorrection risk

— Avoid concurrent fluid restriction during initiation

Hypertonic (3%) saline:

Isotonic saline (0.9%): 154 mEq/L Na; first-line for hypovolemic hyponatremia; contraindicated in SIADH (will paradoxically worsen Na because the kidney excretes the Na in concentrated urine while retaining the water — the "desalination" effect)

Fluid restriction: mainstay of chronic SIADH and hypervolemic states; <800 mL/day for severe SIADH.

Salt tablets: 1–3 g PO TID adjunct in SIADH.

Loop diuretics (furosemide): disrupt medullary concentration gradient → impair urine concentration → free water loss. Useful in SIADH (especially with salt tabs) and essential in hypervolemic hyponatremia.

Urea: 15–30 g PO daily — induces osmotic diuresis; effective in chronic SIADH; well tolerated, no overcorrection risk.

Vasopressin receptor antagonists (vaptans):

Demeclocycline: historical agent (induces nephrogenic DI); rarely used due to nephrotoxicity.

DDAVP (desmopressin): counterintuitively used as a rescue/prophylactic "clamp" to prevent or reverse overcorrection — give 2–4 mcg IV with D5W if Na rising too fast.

Step 3 management: in SIADH, never give isotonic saline alone — pair with a loop diuretic if you must use it, or stick to fluid restriction. Boards test this exact error.

Board pearl: vaptans are contraindicated in hypovolemic hyponatremia and in cirrhosis (hepatotoxicity, increased mortality signal).

Procedures and Expanded Pharmacology Decisions

— Na deficit (mEq) = TBW × (target Na − actual Na)

— TBW = 0.6 × kg (men), 0.5 × kg (women), 0.45 × kg (elderly women)

— Example: 60 kg elderly woman, Na 115, target 121 over 24 h → 0.45 × 60 × (121−115) = 162 mEq ≈ 320 mL of 3% saline over 24 h

— 3% saline: 513 mEq/L

— 0.9% saline: 154 mEq/L

— Underestimates rise when ADH suddenly turns off (hypovolemia corrected, glucocorticoids replaced, drug withdrawn) — anticipate water diuresis and overshoot

— Triggers: thiazide stopped, hypovolemia corrected, cortisol replaced, DDAVP discontinued, MDMA/desmopressin metabolized

— Watch urine output: a sudden rise from 30 mL/h to 300 mL/h heralds free water diuresis → Na will spike

— Action: D5W 6 mL/kg over 1–2 h ± DDAVP 2–4 mcg IV/SC q6–8h

— Give DDAVP 2 mcg IV q8h to lock ADH on

— Co-administer 3% saline at calculated rate for controlled, predictable rise

— Prevents overcorrection completely; increasingly standard of care

— Post-TURP syndrome: absorption of glycine/sorbitol irrigation → dilutional + translocational hyponatremia + neuro symptoms + visual changes. Stop irrigation, hypertonic saline if severe.

— Marathon/endurance: restrict fluids, hypertonic saline if symptomatic; do not give isotonic fluids (worsens with desalination)

Calculating sodium deficit (less used clinically, still board-relevant):

Adrogue-Madias formula: ΔNa per liter infusate = (Infusate Na − Serum Na) / (TBW + 1)

Managing the "ADH switch-off" overcorrection:

Proactive "DDAVP clamp" protocol (high-risk patients, Na <120):

Procedural settings to know:

CCS pearl: when you order 3% saline, also order q2h Na, strict I/Os, urine output q1h, and neuro checks q2h. Document the upper-limit correction target (e.g., "do not exceed Na 124 in next 24 h from baseline 117").

Board pearl: the most dangerous moment in any hyponatremia case is when ADH suddenly switches off — anticipate it whenever you correct a reversible driver.

Special Populations — Elderly and Renal/Hepatic Impairment

— Age-related decline in free water excretion, blunted thirst, polypharmacy, reduced lean mass (lower TBW)

— Thiazide-induced hyponatremia: classic vignette — elderly woman started on HCTZ 2–3 weeks earlier, presents with falls or confusion, Na 118

— Mechanism: thiazides block Na reabsorption in cortical diluting segment → impair maximal urine dilution → water retention; also volume contraction stimulates ADH

— Treatment: stop thiazide, replete K and Mg, gentle volume repletion; expect rapid correction once thiazide effect wanes → anticipate ADH switch-off and overshoot

— Do not restart thiazide; use alternative antihypertensive (ACEi, ARB, amlodipine)

— Impaired free water excretion at GFR <30; even modest hypotonic intake causes hyponatremia

— Treatment: fluid restriction; loop diuretics retain efficacy; avoid vaptans in advanced CKD (limited data, reduced efficacy)

— Dialysis can correct severe hyponatremia but rate must be controlled to avoid ODS

— Hypervolemic hyponatremia from splanchnic vasodilation → effective arterial underfilling → ADH activation

— Na <130 predicts mortality and increases hepatic encephalopathy risk

— Treatment: fluid restriction (<1.5 L/day), albumin, midodrine/octreotide, large-volume paracentesis with albumin

— Avoid tolvaptan (hepatotoxicity, mortality signal in cirrhosis)

— Liver transplant evaluation if Na persistently <130

— Same physiology — low effective circulating volume → ADH activation

— Treatment: loop diuretics, ACEi/ARB/ARNI, SGLT2 inhibitor (also raises Na modestly), fluid restriction

— Tolvaptan can be used short-term for severe symptomatic hyponatremia in HF

Elderly — highest-risk demographic:

CKD:

Cirrhosis:

Heart failure:

Key distinction: in cirrhosis and HF, giving isotonic saline worsens hyponatremia and edema — the kidney excretes the Na while retaining the water. Restrict water; don't push salt.

Step 3 management: elderly patient with thiazide hyponatremia — discontinue thiazide, hold all hypotonic fluids, monitor Na q6h for 48 h, and pre-position D5W + DDAVP in case of overcorrection.

Special Populations — Pregnancy, Pediatrics, and Postoperative

— Normal pregnancy: serum Na set point drops ~5 mEq/L (reset osmostat from hCG-mediated mechanisms); Na 130–135 is physiologic — do not treat

— Preeclampsia/HELLP can worsen hyponatremia

— Oxytocin during labor has antidiuretic activity, especially when given in hypotonic fluids → iatrogenic hyponatremia in laboring women and neonatal hyponatremic seizures

— Prevention: use isotonic fluids with oxytocin; avoid D5W

— Acute fatty liver of pregnancy and severe hyperemesis can produce hyponatremia

— Hospitalized children: isotonic maintenance fluids (0.9% NS with dextrose) are now standard — hypotonic maintenance (¼ or ½ NS) historically caused fatal hospital-acquired hyponatremic encephalopathy (AAP 2018)

— Children have higher brain-to-skull ratio → less reserve for cerebral edema → present with seizures at higher Na levels than adults

— Treatment of symptomatic pediatric hyponatremia: 3% saline 2 mL/kg bolus (max 100 mL) over 10 min, may repeat twice

— Pain, nausea, opioids, PEEP, and stress all stimulate ADH

— Combined with routine postop hypotonic IVF (D5 ½NS) → classic postop Na 120 vignette

— Prevention: isotonic maintenance fluids postoperatively

— Particularly hazardous in young menstruating women (estrogen reduces Na-K-ATPase activity in brain → enhanced cerebral edema risk)

— Exercise-associated hyponatremia from excess hypotonic intake plus non-osmotic ADH release

— Treatment: fluid restriction; hypertonic saline if symptomatic; do not give isotonic fluids

— Primary polydipsia (schizophrenia), MDMA use at raves (acute, severe, often fatal), SSRI-induced SIADH (especially elderly, within first 2–4 weeks)

Pregnancy:

Pediatrics:

Postoperative SIADH:

Marathon/endurance athletes:

Psychiatric patients:

Board pearl: young woman with seizure at a music festival + Na 118 = MDMA-induced hyponatremia — hypertonic saline now, do not delay.

Step 3 management: any hospitalized child requiring maintenance IVF gets isotonic fluids — this is a tested patient-safety standard.

Complications and Adverse Outcomes

— Water shifts into brain cells; with <48 h to adapt, intracranial pressure rises

— Manifestations: headache, vomiting, seizure, obtundation, tonsillar herniation, respiratory arrest, non-cardiogenic pulmonary edema (neurogenic)

— Young menstruating women and children at highest risk

— Treatment: hypertonic saline urgently

— Caused by overly rapid correction of chronic hyponatremia (>8–10 mEq/L in 24 h or >18 in 48 h)

— Mechanism: brain has extruded osmolytes during chronic adaptation; rapid Na rise dehydrates oligodendrocytes → demyelination, especially in pons (but also basal ganglia, thalamus, cerebellum — "extrapontine")

— Biphasic course: initial neurologic improvement with correction, then 2–6 days later → dysarthria, dysphagia, spastic quadriparesis, "locked-in" syndrome, seizures, coma, death

— MRI: T2 hyperintensity in central pons (often delayed 1–3 weeks)

— High-risk substrates: Na <105, hypokalemia, malnutrition, alcoholism, advanced liver disease, hypoxia, burns

— Treatment: largely supportive; some role for re-lowering Na with D5W/DDAVP if caught early; recovery variable (some full, some devastating)

— Even mild chronic hyponatremia (Na 130–134) increases fall risk, fractures, and osteoporosis (Na efflux from bone matrix mobilizes calcium)

— Strong association with hip fracture in elderly — correcting chronic hyponatremia reduces falls

Cerebral edema (acute hyponatremia):

Osmotic demyelination syndrome (ODS, formerly central pontine myelinolysis):

Falls and fractures:

Cognitive impairment: subtle attention/gait deficits at Na 125–134 reversible with correction.

Mortality: in-hospital Na <135 independently increases mortality across virtually every disease (CHF, cirrhosis, pneumonia, MI, stroke, sepsis).

Key distinction: cerebral edema kills early (hours); ODS kills late (days) — both come from getting the correction rate wrong in opposite directions.

Board pearl: any patient who neurologically worsens 2–6 days after Na correction has ODS until proven otherwise. Document the correction trajectory in your note — this is a malpractice landmine.

When to Escalate Care — ICU, Consult, Inpatient Triage

— Any patient receiving 3% hypertonic saline (need q2h Na, neuro checks, possible airway)

— Seizures, obtundation, coma, herniation signs

— Severe hyponatremia (Na <120) with any symptoms

— Suspected or evolving ODS

— Postoperative neurosurgical patients with hyponatremia

— MDMA/ecstasy-related severe hyponatremia

— Symptomatic Na 120–129 without seizure/coma

— Asymptomatic Na <120

— New thiazide-induced hyponatremia requiring monitoring during ADH switch-off

— Need for fluid restriction trial that requires monitored I/Os

— Suspected adrenal insufficiency or myxedema coma

— Asymptomatic chronic Na 130–134 in stable patient with identified cause

— Chronic SIADH on stable fluid restriction

— Cirrhosis/CHF with stable baseline hyponatremia and reliable follow-up

— Nephrology: Na <125, diagnostic uncertainty, refractory SIADH, need for vaptan initiation, suspected CSW vs SIADH

— Endocrinology: suspected adrenal insufficiency, SIADH with unclear etiology, pituitary disease

— Oncology: SCLC or other malignancy-related SIADH

— Neurosurgery/neurology: SAH, TBI with hyponatremia; suspected ODS

Admit to ICU:

Admit to ward (telemetry or general):

Outpatient management acceptable:

Consultations:

CCS pearl: when you order 3% saline outside an ICU, move the patient to ICU first or simultaneously — Step 3 graders watch for inappropriate location of high-acuity therapies. "Transfer to ICU" should be an explicit order.

Step 3 management: for the elderly patient with thiazide hyponatremia and Na 118 + confusion, the correct disposition is admission to a monitored bed (step-down or ICU) with q4–6h Na, hold thiazide, IV access, and standing orders for D5W + DDAVP if overcorrection occurs. Do not discharge from the ED even if the patient looks well — the ADH switch-off is coming.

Key Differentials — Within Hypotonic Hyponatremia

— Renal losses (UNa >20): thiazides, ACEi/ARB-mineralocorticoid effects, cerebral salt wasting, salt-wasting nephropathy, adrenal insufficiency, osmotic diuresis (glucose, mannitol, urea)

— Extrarenal losses (UNa <20): vomiting (paradoxically high UCl is low; UNa may be elevated from bicarbonaturia), diarrhea, sweating, burns, pancreatitis, bowel obstruction (third-space)

— SIADH: CNS disease, pulmonary disease (SCLC, pneumonia, TB), drugs (SSRIs, carbamazepine, oxcarbazepine, cyclophosphamide, vincristine, MDMA), idiopathic in elderly, HIV, postoperative

— Hypothyroidism (severe): reduced cardiac output → ADH stimulation; usually myxedema-level disease

— Glucocorticoid deficiency: secondary adrenal insufficiency (pituitary); cortisol normally suppresses ADH

— Primary polydipsia (UOsm <100): psychiatric patients; intake exceeds renal free-water excretion capacity (~15–20 L/day in normal kidneys)

— Beer potomania / "tea and toast" (UOsm <100): low solute intake limits free water excretion; common in alcoholics and frail elderly

— Reset osmostat: Na stable 125–135, no treatment needed

— CHF: ADH activated by low effective arterial volume

— Cirrhosis: splanchnic vasodilation → effective underfilling

— Nephrotic syndrome: controversial — overflow vs underfill theories; ADH still active

— Advanced CKD/AKI: impaired water excretion

Hypovolemic causes (UNa varies by source):

Euvolemic causes (UNa typically >40, UOsm >100):

Hypervolemic causes (UNa typically <20 except in CKD):

Key distinction: SIADH vs CSW — both have UNa >40, UOsm >100, low uric acid. Only volume status separates them: SIADH is euvolemic, CSW is hypovolemic. Treatment is opposite. CSW classically follows SAH within 1–2 weeks.

Board pearl: the elderly nursing home patient with Na 128, dilute urine (UOsm 80), and a diet of toast, tea, and beer = low-solute hyponatremia. Treat with increased dietary protein and solute, not hypertonic saline.

Key Differentials — Other-Category Mimics

— Lab artifact from indirect ion-selective electrodes when plasma water fraction is reduced

— Causes: severe hypertriglyceridemia (>1500 mg/dL), severe hyperproteinemia (multiple myeloma, Waldenström, IVIG infusion)

— Direct ISE (blood gas analyzer) gives true Na — order an ABG to confirm

— No treatment needed for the Na itself

— Hyperglycemia: corrected Na = measured Na + 1.6–2.4 × (glucose − 100)/100; treating hyperglycemia normalizes Na

— Mannitol (cerebral edema treatment)

— Glycine/sorbitol/mannitol irrigation (TURP, hysteroscopy)

— Maltose (IVIG carrier)

— Radiocontrast

— Primary (Addison): hyponatremia + hyperkalemia + hypotension + hyperpigmentation; aldosterone deficient

— Secondary (pituitary): hyponatremia without hyperkalemia (aldosterone preserved); cortisol low, ACTH low

— Always check morning cortisol + ACTH stim in unexplained hyponatremia

— SSRIs, SNRIs (especially first month, especially elderly)

— Thiazides

— Carbamazepine, oxcarbazepine, valproate

— Cyclophosphamide, vincristine, ifosfamide

— MDMA, opioids

— DDAVP (intentional or factitious)

— NSAIDs, PPIs

Pseudohyponatremia (normal serum osmolality):

Translocational (hypertonic) hyponatremia:

Adrenal insufficiency (commonly misdiagnosed as SIADH):

Hypothyroidism: severe (myxedema) only; check TSH in every workup

CSW vs SIADH (revisited): volume status, BUN/Cr ratio (elevated in CSW), response to saline (corrects CSW, worsens SIADH)

Drug-induced (a separate mental category to scan):

Step 3 management: every hyponatremia workup includes a complete medication review — discontinuing the offending agent is often the entire treatment.

Board pearl: the patient with Na 128, glucose 600, and altered mental status doesn't need saline for the Na — they need insulin and isotonic fluids for DKA/HHS, and the Na will normalize as glucose falls.

Secondary Prevention and Long-Term Plan

— Discontinue offending drug (thiazide, SSRI, carbamazepine) and switch class

— Treat malignancy (chemo for SCLC often resolves paraneoplastic SIADH)

— Adequate cortisol/thyroid replacement

— Optimize HF/cirrhosis with disease-specific therapy

— Step 1: fluid restriction to <1000 mL/day (or less if urine Na+K > serum Na)

— Step 2: add salt (≥6–9 g/day) ± loop diuretic (furosemide 20–40 mg)

— Step 3: urea 15–30 g PO daily — well tolerated, no overcorrection, inexpensive

— Step 4: tolvaptan — reserved for refractory cases, limited to <30 days, hepatotoxicity monitoring; initiate inpatient

— Sodium <2 g/day and fluid <1.5 L/day

— Loop diuretic ± thiazide synergy (carefully — risk of worsening Na)

— Guideline-directed medical therapy for HF (ACEi/ARB/ARNI, beta-blocker, MRA, SGLT2i — note SGLT2i modestly raises Na)

— Cirrhosis: spironolactone + furosemide, midodrine, paracentesis with albumin; consider transplant listing

— Avoid thiazides as antihypertensive of choice in recurrent hyponatremia

— Caution with SSRIs in elderly — counsel on symptoms, recheck Na at 2 and 4 weeks

— Avoid combination of thiazide + SSRI + NSAID in elderly (triple ADH/Na-handling hit)

Identify and address the driver — this is the durable fix:

Chronic SIADH outpatient regimen (stepwise):

Hypervolemic outpatient regimen:

Beer potomania / low-solute: increase dietary protein and salt; address alcohol use disorder.

Primary polydipsia: behavioral therapy, fluid restriction, treat underlying psychiatric disease, consider switching antipsychotic.

Medication review at discharge — Step 3 patient-safety touchstone:

Vaccination and bone health: chronic hyponatremia → osteoporosis; ensure DEXA, calcium, vitamin D in chronic SIADH patients.

Step 3 management: at discharge from a thiazide-hyponatremia admission, the medication reconciliation must show thiazide removed and replaced (e.g., with amlodipine or losartan), with a documented "do not restart thiazide" note in the problem list.

Follow-Up, Monitoring, and Counseling

— Severe: Na q2h during 3% saline, then q4h once stable

— Moderate: Na q4–6h

— Strict I/Os; urine output q1–2h (sudden rise = ADH switch-off → overcorrection imminent)

— Daily weights, neuro checks q2–4h

— Continuous telemetry if K shifts or severe disease

— Recheck BMP at 48–72 hours after discharge

— Then weekly × 2–4 weeks until stable

— Monthly for 3 months

— Every 3–6 months thereafter for chronic SIADH on therapy

— Recheck 2 and 4 weeks after starting any SSRI, SNRI, thiazide, or carbamazepine in elderly

— Fluid restriction practical advice: measure fluid intake, count soup/ice cream/popsicles, use a marked bottle, sip rather than gulp; suck on ice chips, sour candies for thirst

— Recognize warning symptoms: headache, nausea, confusion, gait instability → seek care

— Medication adherence and follow-up labs are non-negotiable

— Avoid OTC NSAIDs (potentiate ADH)

— Limit alcohol (beer potomania risk in cirrhosis and elderly)

— Post-ODS: PT/OT, speech therapy for dysarthria/dysphagia, often prolonged rehab

— Post-hyponatremic encephalopathy: cognitive rehab, fall-prevention assessment in elderly

— Bone health: DEXA in chronic hyponatremia; treat osteoporosis aggressively

— Documented correction rate in chart

— Medication reconciliation showing offending drug action

— Discharge education documented

Inpatient monitoring during active correction:

Post-discharge follow-up cadence:

Patient/family counseling points:

Rehabilitation:

Quality measures:

CCS pearl: on every CCS hyponatremia case, after stabilization, advance the clock to obtain a follow-up Na the next morning and again 48 hours later, and explicitly schedule outpatient follow-up — graders reward longitudinal management.

Board pearl: in elderly patients started on an SSRI, rechecking Na at 2 and 4 weeks is the highest-yield prevention intervention and frequently tested.

Ethical, Legal, and Patient Safety Considerations

— ODS is largely iatrogenic and a major source of malpractice claims

— Document baseline Na, correction targets, q2h checks, and contingency plans (D5W/DDAVP available) — defensible care

— Hospitals increasingly use mandatory order-set guardrails for 3% saline (max rate, mandatory Na recheck intervals); follow them

— Tolvaptan: discuss hepatotoxicity risk, 30-day limit, and need for LFT monitoring; obtain documented consent in cirrhosis exclusion

— Hypertonic saline in altered/obtunded patients: emergency exception (implied consent); notify surrogate as soon as feasible

— ED-to-floor: communicate baseline Na, correction trajectory, last DDAVP/3% saline dose, hold parameters

— Floor-to-discharge: clear medication reconciliation (thiazide removed, SSRI considered, NSAIDs avoided), follow-up labs scheduled, problem-list update

— Post-discharge to PCP: dedicated note flagging hyponatremia history and trigger

— MDMA-related hyponatremia in adolescents: report suspected drug use per state law; involve social work, harm-reduction counseling

— Adult protective services if neglect contributes (e.g., dehydrated nursing home patient with hyponatremia from inadequate care)

— Pediatric hyponatremic seizure from hypotonic IVF — hospital incident report; system-level review of fluid order sets

— Severe hyponatremia produces encephalopathy → patient lacks capacity for major decisions until corrected; reassess capacity after Na normalizes

— Document capacity status when consenting for procedures

— Older women on thiazides represent a high-risk, often under-monitored population — ensure proactive Na surveillance

— Patients with limited health literacy need plain-language fluid restriction instructions and teach-back

Overcorrection as a patient-safety event:

Informed consent edge cases:

Transitions of care — high-risk handoffs:

Mandatory reporting and public health:

Capacity assessment:

Health equity considerations:

Step 3 management: when an elderly patient has thiazide-induced hyponatremia, the discharge process should include placing "thiazide allergy/intolerance" or equivalent flag in the EMR, communicating with the PCP, and counseling the patient/family — this is a tested transition-of-care expectation.

Board pearl: a documented correction plan in the chart is your best protection — write your Na targets and limits before starting therapy.

High-Yield Associations and Rapid-Fire Clinical Facts

— Elderly woman + thiazide + falls → thiazide-induced hyponatremia

— Smoker + chronic SIADH + weight loss → SCLC (chest CT)

— SAH/TBI + hyponatremia + hypovolemia → cerebral salt wasting

— SAH/TBI + hyponatremia + euvolemia → SIADH

— Marathon finisher + confusion → exercise-associated hyponatremia

— Rave/festival + young woman + seizure → MDMA

— Schizophrenic patient + dilute urine + Na 120 → primary polydipsia

— "Tea and toast" elderly + Na 128 → low-solute (beer potomania variant)

— Postop day 1 + D5½NS + headache → iatrogenic SIADH

— Hyponatremia + hyperkalemia + hypotension → adrenal insufficiency

— Hyponatremia + glucose 600 → translocational (correct Na formula)

— Hyponatremia + TG 4000 → pseudohyponatremia

— Na corrected fast 4 days ago, now dysarthric → ODS

— Correction limits: ≤8 mEq/L per 24 h, ≤18 per 48 h (≤6 in high-ODS-risk)

— 3% saline bolus: 100 mL over 10 min × up to 3

— Hyperglycemia correction: +1.6 to 2.4 mEq Na per 100 mg/dL glucose >100

— Serum osm normal: 275–295 mOsm/kg

— SIADH urine: UOsm >100, UNa >40, low uric acid

— DDAVP rescue: 2–4 mcg IV + D5W if overcorrecting

— Tolvaptan: <30 days, hepatotoxic, inpatient initiation

— Urine (Na+K) < serum Na → fluid restriction will work

— Urine (Na+K) > serum Na → free water is being generated; restriction alone will fail; add salt, loop diuretic, urea, or vaptan

Classic associations — pattern-match these instantly:

Rapid-fire numbers:

Drugs causing SIADH (mnemonic SIADH): SSRIs, Ifosfamide/cyclophosphamide, Anticonvulsants (carbamazepine, oxcarbazepine, valproate), Diuretics (thiazides, mechanistically distinct but tested together), Haloperidol/antipsychotics; plus MDMA, opioids, vincristine, NSAIDs, DDAVP, PPIs.

Board pearl: urine Na+K vs serum Na predicts response to fluid restriction in SIADH:

Key distinction: UOsm <100 = no ADH (polydipsia, low solute); UOsm >100 = ADH on (everything else).

Board Question Stem Patterns

— 78-year-old woman on HCTZ for 3 weeks, found confused after a fall. Na 116, K 3.2, urine osm 320, urine Na 45, euvolemic on exam. Next step?

— Answer: Stop HCTZ, admit, replete K, hold hypotonic fluids, monitor Na q4–6h, prepare to give D5W/DDAVP if overcorrection occurs. Trap answer: "Start hypertonic saline" — she's asymptomatic enough not to need it.

— Young woman post-marathon, Na 118, now seizing. Next step?

— Answer: 3% saline 100 mL IV bolus over 10 min. Trap: normal saline, fluid restriction, head CT first.

— 65-year-old smoker, Na 124, euvolemic, UOsm 480, UNa 60, normal TSH and cortisol, CXR negative. Next best test?

— Answer: Low-dose chest CT for occult SCLC.

— DKA patient, Na 128, glucose 720. Best initial action?

— Answer: Treat DKA with insulin and isotonic fluids; corrected Na is normal.

— Patient with chronic Na 110 received 3% saline; Na now 125 at 12 hours and urine output rising. Next step?

— Answer: Stop hypertonic saline, give D5W ± DDAVP 2 mcg IV to re-lower Na and clamp ADH.

— Patient corrected from 105 to 130 in 24 h, neurologically improved, but 4 days later develops dysarthria and quadriparesis. Diagnosis?

— Answer: Osmotic demyelination syndrome.

— Post-SAH day 7, Na 126, UNa 70, UOsm 500, orthostatic hypotension and weight loss. Treatment?

— Answer: Isotonic saline (CSW) — not fluid restriction.

— Hypotensive patient, Na 124, K 5.8, eosinophilia. Next step?

— Answer: Stress-dose hydrocortisone after drawing cortisol + ACTH.

— Cirrhotic with ascites, Na 126, edematous. Treatment?

— Answer: Fluid + sodium restriction + spironolactone/furosemide. Trap: normal saline (worsens it), tolvaptan (hepatotoxic).

Stem 1 — Thiazide vignette:

Stem 2 — Severe symptomatic:

Stem 3 — SIADH workup:

Stem 4 — Translocational:

Stem 5 — Overcorrection:

Stem 6 — ODS:

Stem 7 — CSW vs SIADH:

Stem 8 — Adrenal:

Stem 9 — Cirrhosis:

Board pearl: when stem highlights rate of correction or duration <48 h, the test is asking about ODS vs cerebral edema balance — always quote the 6–8 mEq/24 h ceiling explicitly in your reasoning.

One-Line Recap

Hyponatremia management is a three-step decision tree: confirm true hypotonic hyponatremia (low serum osm), classify by volume status and urine studies (UOsm, UNa), then treat the cause while respecting correction rate limits (≤6–8 mEq/L per 24 h) to avoid both cerebral edema and osmotic demyelination.

Triad to order first: serum osmolality + urine osmolality + urine sodium — these three labs resolve nearly every case before you commit to therapy.

Severity > number: seizures, coma, or severe vomiting at any Na → 3% saline 100 mL bolus regardless of chronicity, targeting a 4–6 mEq/L rise; asymptomatic chronic hyponatremia → treat the cause slowly.

Volume status drives fluid choice: hypovolemic → isotonic saline (watch for ADH switch-off overcorrection); euvolemic SIADH → fluid restriction ± salt/loop/urea/vaptan, never isotonic saline alone; hypervolemic CHF/cirrhosis → water and sodium restriction plus loop diuretic, never saline.

Anticipate overcorrection whenever a reversible ADH driver is removed (thiazide stopped, volume restored, cortisol replaced, DDAVP cleared) — pre-position D5W ± DDAVP 2–4 mcg to re-lower Na if you exceed 8 mEq/L in 24 h, and document your correction targets in the chart before starting therapy.

Step 3 management essentials: check TSH and morning cortisol in every unexplained case, review every medication (SSRIs, thiazides, carbamazepine, NSAIDs, opioids), screen for occult malignancy (chest CT in older smokers with idiopathic SIADH), schedule a 48–72 h post-discharge BMP, and flag offending drugs in the EMR to prevent recurrence — these longitudinal touches are what distinguish Step 3 answers from Step 2 answers on hyponatremia vignettes.